新辅助直肠(NAR)评分:评估新辅助治疗疗效及术后预后价值
基于瑞典结直肠癌注册库9978例非转移性直肠癌手术患者,验证NAR评分在不同新辅助方案中的预后价值。不同治疗间NAR评分均值差异显著(p<0.0001),(化)放疗+额外化疗最低为16.3。低NAR评分(<8)较高评分(>16)患者的总生存(OS)和无复发时间(TTR)显著更优(p<0.05),但NAR评分模型C指数(0.623)未优于仅用病理T、N分期(0.646)。
要点
- NAR评分在不同新辅助治疗间差异显著,可区分不同细胞杀伤效应的方案。
- 低NAR评分(<8)较高评分(>16)患者OS和TTR显著更优。
- NAR评分预后价值不优于病理T、N分期,但可作为临床试验中更简便的替代方法。
核心结论
- NAR评分具有预后价值,但不优于病理T分期和N分期。
- NAR评分仍可区分两种细胞杀伤效应不同的治疗,可能在临床试验中作为比病理T、N分期更简便的方法。
研究设计与样本
- 研究纳入2007-2015年瑞典结直肠癌注册库中所有9978例接受手术的非转移性直肠癌患者。
- 感兴趣的患者接受短程放疗(scRT)/化放疗(CRT)+延迟手术、长程放疗+延迟手术、(化)放疗+额外化疗、直接手术或scRT+立即手术。
- scRT/CRT+延迟手术组根据手术时间进一步分组。
主要发现
- 不同治疗间NAR评分均值差异显著(p<0.0001)。
- (化)放疗+额外化疗组NAR评分均值最低,为16.3;CRT+延迟手术组为17.7。
- 在CRT和scRT患者中,低NAR评分(<8)与高评分(>16)患者的总生存(OS)和无复发时间(TTR)差异显著(p<0.05),CRT患者相关性更强。
- NAR评分模型的C指数为0.623,未优于仅使用病理T和N分期的模型(0.646)。
关键数值与推荐
- NAR评分低值定义为<8,高值定义为>16。
- (化)放疗+额外化疗组NAR评分均值为16.3,CRT+延迟手术组为17.7。
- NAR评分模型C指数为0.623,病理T和N分期模型C指数为0.646。
临床怎么用
- NAR评分可用于评估新辅助治疗疗效和预后,但不应替代病理T、N分期。
- 在临床试验中,NAR评分可作为比病理T、N分期更简便的替代终点,用于区分不同细胞杀伤效应的治疗。
局限性
- NAR评分最初基于化放疗(CRT)且手术延迟6-8周开发,本研究探索了其他方案。
- NAR评分预后价值不优于病理T、N分期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The Neoadjuvant rectal (NAR) score is a new surrogate endpoint to be used in clinical trials for early determination of treatment response to different preoperative therapies. The aim is to further validate the NAR-score, primarily developed using chemoradiotherapy (CRT) with a delay to surgery 6-8 weeks, and explore its value using other schedules. MATERIALS AND METHODS: The study included all 9978 patients diagnosed with non-metastasized RC in 2007-2015 that had undergone surgery and was registered in the Swedish Colorectal Cancer Registry. The patients of interest had either short-course radiotherapy (scRT)/CRT + delayed surgery, long-course radiotherapy (RT) + delayed surgery, (C)RT + additional chemotherapy, primary surgery, or scRT + immediate surgery. The scRT/CRT + delayed surgery groups were further divided based on time to surgery. RESULTS: Mean NAR-score differed significantly (p < 0.0001) between different treatments. (C)RT + additional chemotherapy had the lowest mean score of 16.3 and CRT + delayed surgery had 17.7. There was a significant difference (p < 0.05) in overall survival (OS) and time to recurrence (TTR) of patients with a Low NAR-score (<8) compared to those with a High score (>16) for both CRT- and scRT, with a stronger correlation for CRT-patients. C-index for the NAR-score model (0.623) was not superior to when only pathological T- and N-stage was used (0.646). CONCLUSIONS: The NAR-score is prognostic, but it is not better than pT- and pN-stage. However, the NAR-score can still discriminate between two treatments that have different cell killing effect and may still be of value in clinical trials as an easier method than pT- and N-stage.
引用
- Imam I, Hammarström K, Sjöblom T, et al. Neoadjuvant rectal (NAR) score: Value evaluating the efficacy of neoadjuvant therapy and prognostic significance after surgery? Radiother Oncol. 2021. PMID: 33453311. doi:10.1016/j.radonc.2021.01.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。